---
schema_version: "secwatch.filing_event.v1"
accession: "0001493152-24-008670"
form_type: "8-K"
ticker: "INDP"
cik: "0001857044"
company_name: "Indaptus Therapeutics, Inc."
filed_at: "2024-03-04T23:59:59+00:00"
generated_at: "2026-06-05T05:01:31.828627+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# Indaptus reports positive Phase 1 results for Decoy20; moves to multi-dose trial

## Summary
- Second cohort of Phase 1 INDP-D101 trial showed broad immune response consistent with first cohort.
- Independent Safety Review Committee recommended continuing to multiple doses of Decoy20.
- Company has started screening patients for multi-dose safety and efficacy across multiple cancer types.
- Animal models demonstrated Decoy20 safety in several multiple-dose schedules.

## SEC filing metadata
- accession: 0001493152-24-008670
- form_type: 8-K
- ticker: INDP
- cik: 0001857044
- company_name: Indaptus Therapeutics, Inc.
- filed_at: 2024-03-04T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 8.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1857044/000149315224008670/0001493152-24-008670-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1857044/000149315224008670/form8-k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001493152-24-008670
- JSON: https://secwatch.observer/filing/0001493152-24-008670.json
- Plain text: https://secwatch.observer/filing/0001493152-24-008670.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.